FOXP3 and colorectal carcinoma: Interestingly, a higher expression of FoxP3 (a marker of Tregs) has been demonstrated in patients with pMMR/MSI-L CRC than in those with dMMR/MSI-H CRC, indicating a deeper degree of immunosuppression in these patients.